 |
answer text |
<p>The United Kingdom Rare Disease Strategy, published in 2013, sets out our commitment
to raising awareness about all rare diseases including idiopathic pulmonary fibrosis
(IPF) and our strategic vision for improving the lives of all those affected. The
Strategy promotes improvements to ensure that people living with a rare disease receive
high-quality care.</p><p>The Government recognizes the need for awareness raising
and training of health care professionals for rare diseases. This is being taken forward
through the work of the UK Rare Diseases Policy Board and NHS England’s Rare Diseases
Implementation plan, which commits NHS England to engaging with the Royal College
of General Practitioners (GPs) and the Nursing and Midwifery Council on opportunities
for GPs and health visitors to recognise and facilitate earlier diagnosis of rare
diseases.</p><p>There are limited drug treatment options for IPF and two drugs, Pirfenidone
and Nintedanib, are commissioned following National Institute for Health and Care
Excellence Technology Appraisals. Alongside this, the Department funds research into
rare diseases such as IPF through the National Institute for Health Research (NIHR).</p>
|
|
